AIM: The study aims were to characterize risperidone and (±)-9-hydroxyrisperidone pharmacokinetic (PK) variability in children and adolescents and to evaluate covariate effects on PK parameters. METHODS: Steady-state samples were drawn at predose, 1, 2, 4, and 7 hours postdose; cytochrome P450 2D6 (CYP2D6) genotypes were available for 28 subjects. A nonlinear mixed-effects model (NONMEM) modeled the PKs of risperidone and (±)-9-hydroxyrisperidone; covariates included age, weight, sex, and CYP2D6 phenotype. The model included 497 observations [risperidone (n = 163), (+) and (-)-9-hydroxyrisperidone (n = 334)] from 45 subjects aged 3-18.3 (mean 9.6 ± 3.7) years, weighing 16.8-110 (43 ± 20.2) kg. RESULTS: A 1-compartment mixture model described risperidone and (±)-9-hydroxyrisperidone clearances for 3 CYP2D6 metabolizer subpopulations: extensive, intermediate, and poor. Weight significantly affected (±)-9-hydroxyrisperidone clearance. Clearance estimates in the mixture model were poor metabolizer 9.38 L/h, intermediate metabolizer 29.2 L/h, and extensive metabolizer 37.4 L/h. CONCLUSION: Active moiety [risperidone plus (±)-9-hydroxyrisperidone] PK variability and the covariate effects were better explained with the addition of metabolite PK parameters. This model may aid the development of individualized risperidone dosing regimens in children and adolescents.
AIM: The study aims were to characterize risperidone and (±)-9-hydroxyrisperidone pharmacokinetic (PK) variability in children and adolescents and to evaluate covariate effects on PK parameters. METHODS: Steady-state samples were drawn at predose, 1, 2, 4, and 7 hours postdose; cytochrome P450 2D6 (CYP2D6) genotypes were available for 28 subjects. A nonlinear mixed-effects model (NONMEM) modeled the PKs of risperidone and (±)-9-hydroxyrisperidone; covariates included age, weight, sex, and CYP2D6 phenotype. The model included 497 observations [risperidone (n = 163), (+) and (-)-9-hydroxyrisperidone (n = 334)] from 45 subjects aged 3-18.3 (mean 9.6 ± 3.7) years, weighing 16.8-110 (43 ± 20.2) kg. RESULTS: A 1-compartment mixture model described risperidone and (±)-9-hydroxyrisperidone clearances for 3 CYP2D6 metabolizer subpopulations: extensive, intermediate, and poor. Weight significantly affected (±)-9-hydroxyrisperidone clearance. Clearance estimates in the mixture model were poor metabolizer 9.38 L/h, intermediate metabolizer 29.2 L/h, and extensive metabolizer 37.4 L/h. CONCLUSION: Active moiety [risperidone plus (±)-9-hydroxyrisperidone] PK variability and the covariate effects were better explained with the addition of metabolite PK parameters. This model may aid the development of individualized risperidone dosing regimens in children and adolescents.
Authors: E Spina; A Avenoso; G Facciolà; M Salemi; M G Scordo; M Ancione; A G Madia; E Perucca Journal: Psychopharmacology (Berl) Date: 2001-01-01 Impact factor: 4.530
Authors: J E Leysen; W Gommeren; A Eens; D de Chaffoy de Courcelles; J C Stoof; P A Janssen Journal: J Pharmacol Exp Ther Date: 1988-11 Impact factor: 4.030
Authors: Elizabeth Pappadopulos; James C Macintyre Ii; M Lynn Crismon; Robert L Findling; Richard P Malone; Albert Derivan; Nina Schooler; Lin Sikich; Laurence Greenhill; Sarah B Schur; Chip J Felton; Harvey Kranzler; David M Rube; Jeffrey Sverd; Molly Finnerty; Scott Ketner; Sonja E Siennick; Peter S Jensen Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-02 Impact factor: 8.829
Authors: Vidya Perera; Robert R Bies; Gary Mo; Michael J Dolton; Vaughan J Carr; Andrew J McLachlan; Richard O Day; Thomas M Polasek; Alan Forrest Journal: Br J Clin Pharmacol Date: 2014-10 Impact factor: 4.335
Authors: Susan M Abdel-Rahman; Gordon L Amidon; Ajay Kaul; Viera Lukacova; Alexander A Vinks; Gregory T Knipp Journal: Clin Ther Date: 2012-11 Impact factor: 3.393
Authors: Klintean Wunnapuk; Fahim Mohammed; Indika Gawarammana; Xin Liu; Roger K Verbeeck; Nicholas A Buckley; Michael S Roberts; Flora T Musuamba Journal: Br J Clin Pharmacol Date: 2014-10 Impact factor: 4.335
Authors: Kazunari Yoshida; Emiko Koyama; Clement C Zai; Joseph H Beitchman; James L Kennedy; Yona Lunsky; Pushpal Desarkar; Daniel J Müller Journal: Can J Psychiatry Date: 2020-11-23 Impact factor: 5.321
Authors: Thomas Dodsworth; David D Kim; Ric M Procyshyn; Colin J Ross; William G Honer; Alasdair M Barr Journal: Child Adolesc Psychiatry Ment Health Date: 2018-07-16 Impact factor: 3.033